ADGM Adagio Medical Holdings, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2006986 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE9.6%
ROA2.7%
ROIC (approx.)-89.9%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets38.5%
Debt / equity0.11x
Current ratio0.90x
Interest coverage-5.77x
Cash quality & payout
Operating cash flow / net income-22.06x
Accruals ratio61.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | — |
| Cost of revenue | $684,000 | — |
| Gross profit | -$684,000 | — |
| R&D expense | $10.64M | — |
| SG&A expense | $10.57M | — |
| Operating income | -$21.89M | — |
| Interest expense | $2.91M | — |
| Pretax income | -$25.32M | — |
| Income tax | $0 | $0 |
| Net income | -$25.08M | — |
| EBITDA | -$20.92M | — |
| EPS (basic) | -1.51 | — |
| EPS (diluted) | -1.51 | — |
| Weighted avg. shares (diluted) | 16.58M | — |
| Balance sheet | ||
| Cash & equivalents | $17.11M | $20.59M |
| Receivables | — | $35,000 |
| Inventory | $1.67M | $2.57M |
| Current assets | $20.08M | $25.35M |
| PP&E, net | $1.53M | $1.96M |
| Goodwill | $13.97M | $13.97M |
| Intangibles | $6.97M | $6.97M |
| Total assets | $43.25M | $48.45M |
| Current liabilities | $8.23M | $7.76M |
| Long-term debt | $21.04M | $17.18M |
| Total debt | $21.04M | $17.18M |
| Total liabilities | $30.85M | $28.54M |
| Shareholders' equity | $12.40M | $19.91M |
| Net debt | $3.94M | -$3.41M |
| Shares outstanding | 740,348 | 15.20M |
| Cash flow statement | ||
| Operating cash flow | -$19.01M | — |
| Capital expenditure | $374,000 | — |
| Free cash flow | -$19.39M | — |
| Investing cash flow | -$374,000 | — |
| Financing cash flow | $16.13M | — |
| Depreciation & amortization | $970,000 | — |
| Stock-based compensation | $1.48M | — |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.